RxDoctor Payments DataLook up a doctor →

Carlos Rollhauser, MD

Gastroenterology · Knoxville, TNNPI 1407933658

Payments from drug & device makers

$144,318in general payments, 2019–2025

Across 842 payments — averaging $171.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$100K
  • Johnson & Johnson$36K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Gilead$901
  • Bristol Myers Squibb$539
  • Pfizer$478
  • plus $5K from 50 others

What the payments were for

  • Consulting fees$4500%
  • Speaking & faculty fees$110,59777%
  • Travel & lodging$17,16212%
  • Food & beverage$15,84511%
  • Education$1230%
  • Gifts$1430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,318 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$95,700
Medicare patients
467
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab56$1,450,200
XifaxanRifaximin87$285,616
ZenpepLipase/Protease/Amylase40$141,903
Humira(Cf) PenAdalimumab13$90,454
CreonLipase/Protease/Amylase18$75,686
LinzessLinaclotide55$50,230
Mesalamine45$30,714
SutabSod Sulf/Pot Chloride/Mag Sulf72$11,582
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates144$9,557
Sucralfate40$8,000
Pantoprazole Sodium557$7,937
Dexlansoprazole DrDexlansoprazole22$7,814
Colesevelam Hcl35$6,983
MotegrityPrucalopride Succinate13$6,560
Mesalamine ErMesalamine21$6,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$35,743$1,450,20056 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$456$285,61687 claims
Aimmune Therapeutics, Inc.Zenpep$147$141,90340 claims
AbbVieCreon, Linzess$100,312$125,91673 claims
Braintree Laboratories, Inc.Sutab$147$11,58272 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,103$6,56013 claims
SandozLansoprazole$61$3,37812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →